Alumis Inc. ALMS
Set alert
6.73 USD -0.16 -2.32%
At close · Oct 30
6.73 0.00 0.00%
After hours · Oct 30, 4:00 PM ET
6.46 Day range 6.92
4.55 52-week range 30.30
- YTD
- -31.05%
- 1 year
- +44.42%
- Open
- 6.84
- Prev close
- 6.89
- Mkt cap
- 871.10M
- Vol
- 2.24M
- Avg vol
- 2.65M
- EPS
- -3.86
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 6.46
- High
- 6.92
- Forward P/E
- -2.82
- Beta
- -0.79
- Short ratio
- 6.42
- Inst. own
- 93.53%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 12, 2026
- 50-d avg
- 21.50
- 200-d avg
- 22.28
- 1y target
- 32.13
2Y chart
Events in this range
- Aug 13, 2025Earnings: -1.17; estimate -1.11; surprise -5.41%
- Nov 13, 2025Earnings: -1.06; estimate -0.92; surprise -15.22%
- Mar 19, 2026Earnings: -0.95; estimate -0.97; surprise 2.06%
- May 14, 2026Earnings: -0.74; estimate -0.74273; surprise 0.37%
- Aug 13, 2026Earnings: -1.11; estimate -0.767; surprise -44.72%
- Aug 14, 2026Rating: HC Wainwright & Co. · Neutral → Neutral
- Sep 2, 2026Rating: HC Wainwright & Co. · Neutral → Buy
- Sep 2, 2026Rating: Morgan Stanley · Overweight → Overweight
- Sep 2, 2026Rating: Wells Fargo · Overweight → Overweight
- Sep 2, 2026Rating: Oppenheimer · Outperform → Outperform
- Sep 3, 2026Downgrade: Guggenheim · Buy → Neutral
Signals (70)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Sep 22, 2026 | 1 month ago |
| RSI: Oversold | Sep 1, 2026 | 2 months ago |
| SMA: Bearish | Aug 31, 2026 | 2 months ago |
| SMA: Bearish | Aug 11, 2026 | 2 months ago |
| MACD: Sell Signal | Jul 16, 2026 | 3 months ago |
| RSI: Overbought | Jul 7, 2026 | 3 months ago |
| RSI: Overbought | Jun 29, 2026 | 4 months ago |
| SMA: Bullish | Jun 17, 2026 | 4 months ago |
| SMA: Bearish | Jun 16, 2026 | 4 months ago |
| SMA: Bullish | Jun 12, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 11, 2026 | 4 months ago |
| SMA: Bearish | May 15, 2026 | 5 months ago |
| SMA: Bullish | May 13, 2026 | 5 months ago |
| MACD: Sell Signal | May 8, 2026 | 5 months ago |
| SMA: Bearish | May 7, 2026 | 5 months ago |
| SMA: Bullish | May 4, 2026 | 6 months ago |
| SMA: Bearish | Apr 24, 2026 | 6 months ago |
| SMA: Bullish | Apr 22, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 14, 2026 | 6 months ago |
| SMA: Bearish | Mar 18, 2026 | 7 months ago |
| SMA: Bullish | Mar 16, 2026 | 7 months ago |
| SMA: Bearish | Mar 13, 2026 | 7 months ago |
| RSI: Overbought | Feb 19, 2026 | 8 months ago |
| MACD: Sell Signal | Jan 30, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 7, 2026 | 9 months ago |
| RSI: Overbought | Jan 6, 2026 | 9 months ago |
| MACD: Sell Signal | Dec 19, 2025 | 10 months ago |
| RSI: Overbought | Dec 18, 2025 | 10 months ago |
| RSI: Overbought | Nov 14, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 10, 2025 | 11 months ago |
| SMA: Bullish | Nov 6, 2025 | 12 months ago |
| SMA: Bearish | Nov 3, 2025 | 12 months ago |
| MACD: Sell Signal | Nov 3, 2025 | 12 months ago |
| SMA: Bullish | Oct 31, 2025 | 1 year ago |
| SMA: Bearish | Oct 29, 2025 | 1 year ago |
| SMA: Bullish | Oct 27, 2025 | 1 year ago |
| SMA: Bullish | Oct 7, 2025 | 1 year ago |
| MACD: Buy Signal | Oct 7, 2025 | 1 year ago |
| SMA: Bearish | Sep 19, 2025 | 1 year ago |
| SMA: Bullish | Sep 18, 2025 | 1 year ago |
| SMA: Bearish | Sep 16, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 28, 2025 | 1 year ago |
| RSI: Overbought | Aug 15, 2025 | 1 year ago |
| SMA: Bullish | Jul 23, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 24, 2025 | 1 year ago |
| MACD: Sell Signal | May 28, 2025 | 1 year ago |
| SMA: Bearish | May 20, 2025 | 1 year ago |
| SMA: Bullish | May 15, 2025 | 1 year ago |
| SMA: Bearish | May 9, 2025 | 1 year ago |
| SMA: Bullish | May 8, 2025 | 1 year ago |
| MACD: Buy Signal | May 8, 2025 | 1 year ago |
| SMA: Bearish | Apr 14, 2025 | 1 year ago |
| MACD: Sell Signal | Apr 14, 2025 | 1 year ago |
| RSI: Overbought | Apr 4, 2025 | 1 year ago |
| RSI: Overbought | Apr 1, 2025 | 1 year ago |
| SMA: Bullish | Mar 28, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 26, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 20, 2025 | 1 year ago |
| RSI: Oversold | Mar 20, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 28, 2025 | 1 year ago |
| RSI: Oversold | Feb 28, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 26, 2025 | 1 year ago |
| RSI: Oversold | Feb 26, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 24, 2025 | 1 year ago |
| RSI: Oversold | Feb 10, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 7, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 31, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 23, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 14, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 13, 2025 | 1 year ago |
Key statistics
- Market cap
- 1.05B
- Enterprise value
- 556.67M
- Trailing P/E
- 0.00
- Forward P/E
- -2.82
- PEG ratio
- 0.00
- Price / sales
- 141.89
- Price / book
- 2.30
- EPS (TTM)
- -4.11
- Beta
- -0.79
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 7.40M
- Revenue growth
- -37.70%
- Free cash flow
- -208.64M
- Total cash
- 502.29M
- Total debt
- 36.43M
- Return on equity
- -93.65%
- Shares outstanding
- 129.44M
- Short % of float
- 7.27%
- 50-day average
- 21.50
- 200-day average
- 22.28
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 32.13 +377.3% upside
Now 6.73
- Target (low)
- 15.00
- Target (mean)
- 32.13
- Target (high)
- 46.00
Ratings (0m) 10 9 buy · 1 hold · 0 sell
- Strong buy1
- Buy8
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 12, 2026
Expected Nov 12, 2026. Consensus EPS estimate -0.75.
Financials — quick view
ALMS Revenue — quarterly 1.66M
ALMS Net income — quarterly -142.22M
ALMS EPS — quarterly -1.11
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2026 | Sep 30, 2026 | -0.73 | — | — | — |
| Aug 13, 2026 | Jun 30, 2026 | -0.767 | -1.11 | -0.34 | -44.72% |
| May 14, 2026 | Mar 31, 2026 | -0.74273 | -0.74 | 0.00 | +0.37% |
| Mar 19, 2026 | Dec 31, 2025 | -0.97 | -0.95 | +0.02 | +2.06% |
| Nov 13, 2025 | Sep 30, 2025 | -0.92 | -1.06 | -0.14 | -15.22% |
| Aug 13, 2025 | Jun 30, 2025 | -1.11 | -1.17 | -0.06 | -5.41% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 3, 2026 | Guggenheim | down | Buy | Neutral |
| Sep 2, 2026 | Oppenheimer | main | Outperform | Outperform |
| Sep 2, 2026 | Wells Fargo | main | Overweight | Overweight |
| Sep 2, 2026 | Morgan Stanley | main | Overweight | Overweight |
| Sep 2, 2026 | HC Wainwright & Co. | up | Neutral | Buy |
| Aug 14, 2026 | HC Wainwright & Co. | reit | Neutral | Neutral |
About Alumis Inc.
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- alumis.com
News
- Alumis Inc. (NASDAQ:ALMS) Stock Has Consensus Target Price of $33.27
- Alumis New Phase 3 ONWARD Data Show Envudeucitinib Improved Scalp, Itch And Quality Of Life In Psoriasis, Building On 54% PASI 100 At Week 48; NDA On Track For 4Q 2026
- Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures
- Tango Therapeutics (NASDAQ:TNGX) vs. Alumis (NASDAQ:ALMS) Financial Analysis
- Alumis (NASDAQ:ALMS) & Pyxis Oncology (NASDAQ:PYXS) Head-To-Head Review
- Financial Survey: Alvotech (NASDAQ:ALVO) & Alumis (NASDAQ:ALMS)
- Alumis Inc. (ALMS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- 226,618 Shares in Alumis Inc. $ALMS Bought by Bank of New York Mellon Corp
- Alumis to Participate in Upcoming September Investor Conferences
- Oppenheimer Maintains Outperform on Alumis, Lowers Price Target to $37
Your note
Sign in to keep a note on ALMS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AKKARAJU SRINIVAS | Director | Purchase | Sep 7, 2026 | 0 |
| AYURMAYA CAPITAL MANAGEMENT COMPANY, LP | Director and Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | May 20, 2025 | 0 |
| BABLER MARTIN | Chief Executive Officer | Purchase | Mar 31, 2025 | 0 |
| BRADLEY MARK CHRISTOPHER | Officer | Sale | Aug 2, 2026 | 88,585 |
| DRAPPA JORN | Officer | Sale | Aug 2, 2026 | 56,892 |
| FORESITE CAPITAL MANAGEMENT VI, LLC. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Jan 7, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Ayurmaya Capital Management Company, LP | 11.70% | 15,139,707 | 122.78M | Jun 29, 2026 |
| Blackrock Inc. | 6.35% | 8,218,151 | 66.65M | Jun 29, 2026 |
| FMR, LLC | 5.23% | 6,769,170 | 54.90M | Jun 29, 2026 |
| Deep Track Capital, Lp | 4.90% | 6,348,558 | 51.49M | Jun 29, 2026 |
| Samsara BioCapital, LLC | 4.90% | 6,345,219 | 51.46M | Jun 29, 2026 |
| Foresite Capital Management V, LLC | 4.56% | 5,896,995 | 47.82M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.43% | 3,139,756 | 25.46M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.55% | 2,012,064 | 16.32M | Jul 30, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 1.06% | 1,369,916 | 11.11M | Jun 29, 2026 |
| T. ROWE PRICE QUANTITATIVE Mgmt Fd.S, INC.-T. Rowe Price Integrated U. | 0.84% | 1,088,300 | 8.83M | Jun 29, 2026 |
| Fidelity Capital Trust-Fidelity Stock Selector Small Cap Fund | 0.77% | 999,800 | 8.11M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.75% | 977,098 | 7.92M | Jun 29, 2026 |